Watertown, MA, United States of America

Dario Paggiarino

This inventor holds 1 USPTO granted patent and 7 published patent applications and 1 EPO patent. Top assignee: Eyepoint Pharmaceuticals, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Dario Paggiarino: Innovator in Ocular Drug Delivery

Introduction

Dario Paggiarino is a notable inventor based in Watertown, MA (US). He has made significant contributions to the field of ocular drug delivery through his innovative work. His expertise and dedication to advancing medical technology have led to the development of a unique patent.

Latest Patents

Dario holds a patent for a bioerodible ocular drug delivery insert and therapeutic method. This invention relates to implantable bioerodible inserts designed for delivering an active pharmaceutical ingredient to the eye. The patent also encompasses methods of treatment using such inserts, as well as methods of manufacturing these innovative devices.

Career Highlights

Dario is currently associated with EyePoint Pharmaceuticals, Inc., where he continues to work on groundbreaking solutions in the pharmaceutical industry. His role at the company allows him to apply his knowledge and skills in developing advanced drug delivery systems.

Collaborations

Dario collaborates with talented professionals in his field, including Basel Karzoun and Jianbing Chen. These partnerships enhance the innovative efforts at EyePoint Pharmaceuticals, Inc. and contribute to the advancement of ocular therapies.

Conclusion

Dario Paggiarino's work in the field of ocular drug delivery exemplifies the impact of innovation in healthcare. His patent for a bioerodible ocular drug delivery insert represents a significant advancement in the treatment of eye conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…